SciELO - Scientific Electronic Library Online

 
vol.77 número4Vitrificación ovocitaria para posponer fecundidad: experiencia de la Unidad de Medicina Reproductiva de Clínica MonteblancoLeiomioma benigno metastizante: caso clínico con nodulos pulmonares e histerectomía 4 años antes por leiomiomas uterinos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Revista chilena de obstetricia y ginecología

versión On-line ISSN 0717-7526

Resumen

LOPEZ C, Nayara; RAMON G, Natividad; SANCHEZ M, José Ignacio  y  DE SANTIAGO G, Javier. Metástasis óseas múltiples de cáncer de mama: Papel del CA 15.3 y respuesta a la hormonoterapia. Rev. chil. obstet. ginecol. [online]. 2012, vol.77, n.4, pp. 291-295. ISSN 0717-7526.  http://dx.doi.org/10.4067/S0717-75262012000400009.

Bone metastases are involved in a 65-75% of advanced metastatic breast cancer cases. Tumoral markers (CEA, CA 15.3) are useful in the follow-up and evaluation of response to treatment. Hormonal therapy is the optimal treatment option in low grade metastatic breast cancer due to low toxicity and general long term good response. We present a breast cancer case treated with surgery, chemotherapy and radiotherapy. The patient was asymptomatic during the follow-up and multiple bone metastases were diagnosed as a result of an increased CA 15.3 marker found. Hormone therapy was the recommended initial treatment with good response and tolerance. Bone lesions remained stabilized for 7 years but after treatment suspension new bone lesions appeared. CA 15.3 marker had increased again. Reintroduction of hormonal therapy achieved again the stabilization of the lesions.

Palabras clave : Breast carcinoma; bone metastasis; CA 15.3 tumoral marker; hormonal therapy.

        · resumen en Español     · texto en Español     · pdf en Español